Thursday, May 16, 10:16 AM
Navidea Biopharmaceuticals (NAVB) says it's entered into an agreement with Nordion (NDZ -1%) to produce and supply its (123) labeled I-drug NAV5001 for late-phase clinical trials. NDZ will manufacture and supply of NAV5001 clinical trial material by radiolabeling NAVB's precursor drug product with Iodine-123 to form (123)I NAV5001, and then manage the logistics and shipping arrangements to third-party clinical trial sites. The agreement could be a precursor to a commercial supply arrangement in the future.
Comment![Healthcare, Global & FX]
Thursday, April 18, 2:12 PM
Navidea Biopharmaceuticals (NAVB -1.5%) says results from a clinical trial of NAV4694 in healthy subjects and those with diagnosed forms of dementia demonstrated imaging characteristics nearly identical to those of an acknowledged benchmark, gold-standard amyloid imaging agent, 11C-labeled Pittsburgh Compound-B. The authors believe these results show that NAV4694 may be useful in the early and differential diagnosis of Alzheimer’s disease.
Comment![Healthcare, On the Move]
Thursday, April 4, 8:20 AM
Navidea Biopharmaceuticals (NAVB +7.8%) after saying that its Lymphoseek radiopharmaceutical met its primary endpoint in a Phase III trial by identifying sentinel lymph nodes in patients with squamous cell carcinoma (skin cancer) of the head or in the mouth, Until now, expensive surgery has been used. Following the results, the study's Data Safety Monitoring Committee has recommended that Navidea close the trial early. (PR)
Comment![Healthcare, On the Move]
Thursday, April 4, 4:45 AM
The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK).
Wednesday, March 27, 12:04 PM
Navidea Biopharmaceuticals (NAVB +0.8%) bucks a weak tape after saying it's commenced enrollment in Phase 2b positron emission tomography imaging studies of NAV4694, a scan for detecting cerebral-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment. The study is designed to investigate whether scan findings have the ability to distinguish between subjects with MCI who progress to Alzheimer's disease from those who do not.
1 Comment[Healthcare, On the Move]
Thursday, March 21, 9:40 AM
Navidea Biopharmaceuticals' (NAVB +2.2%) Lymphoseek radiopharmaceutical for identifying tumors met the efficacy primary endpoint in two Phase III trials. Lymphoseek, which has been approved by the FDA, demonstrated its "utility and safety" in patients with breast cancer. (PR)
Wednesday, March 13, 1:44 PM
The FDA has approved Navidea Biopharmaceutical's (NAVB -7.4%) Lymphoseek injection, a radioactive imaging agent meant to help doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove the lymph nodes. The drug, which is the first new lymph-node mapping agent approved in more than 30 years, is injected into the tumor area and later, using a hand-held radiation detector, identifies lymph nodes that have taken up Lymphoseek.
8 Comments[Healthcare, On the Move]